Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)—a single region experience on consecutive patients
Eketorp Sylvan, S., Lundin, J., Ipek, M., Palma, M., Karlsson, C., Hansson, L.Volume:
93
Language:
english
Journal:
Annals of Hematology
DOI:
10.1007/s00277-014-2105-1
Date:
October, 2014
File:
PDF, 596 KB
english, 2014